A phase III randomized controlled study on the efficacy and improved bowel function of prolonged ‐release (PR) oxycodone‐naloxone (up to 160/80 mg daily) vs oxycodone PR

ConclusionsOXN PR in daily doses of up to 160/80 mg significantly improves bowel function compared with equivalent doses of OxyPR while still providing comparable analgesic efficacy. SignificanceEffective analgesia can be achieved using oxycodone/naloxone PR up to 160/80 mg daily without compromising bowel function. A similar outcome was reported in cancer and non‐cancer patients. (Source: European Journal of Pain)

MedWorm Message: Have you tried our new medical search engine? More powerful than before. Log on with your social media account. 100% free.

from ! Medicine by Alexandros G. Sfakianakis via alwin on Inoreader http://ift.tt/2tAjxLC
via IFTTT